What’s it about?
New treatment to reduce motor complications of Levodopa therapy in PD subjects experiencing end-of-dose wearing off and Levodopa-induced dyskinesia.
Where is it?
How long does it take?
Who is eligible?
Diagnosis of PD for at least 3 years
2 hrs OFF and 2 hrs dyskinesia per day.
To whom is this relevant?
This Trial may be of interest to anyone with Parkinson’s experiencing end-of-dose wearing-off AND levodopa-induced dyskinesia. There are other criteria to be met. 169 people are required for this Trial.
What is being trialled and where?
This research at Derriford Hospital in Plymouth is part of a European study of the ability the oral drug Foligliurax to reduce the motor complications of levodopa therapy. This is a double-blind randomised placebo-controlled trial, so the Trial team will not know whether you have been assigned the drug or the placebo.
What is involved?
The Trial schedule requires nine visits to Derriford. Visits 1 to 3 are for screening and preparation. Visits 4, 5, 6, 7 and 8 must take place on diarised dates in the 28-day drug trial cycle. Visit 9 is for follow-up . More information is given in the Patient Information Sheet. Travel expenses are paid and free parking can be arranged at the trial unit’s premises.
Interested in taking part?
Please contact Dr Camille Carroll’s research team on 01752 432048 or email firstname.lastname@example.org.
Recruitment for this Trial was expected to close late last year but remains open. This is a Phase 2 trial. Unblinding, which means the record seals are broken by the Trial organisers, takes place at the closure of all participation. As a result you will not be told for some time whether you were taking the placebo or the drug. There are no arrangements for availablity of the drug beyond the 28-day trial. The international trial registration is by Prexton Therapeutics, purchased since registration by the The Lundberg Group.